As a member, Pfizer will have access to clinical data from TriNetX's network of healthcare organizations to support clinical study and protocol design, site identification, and patient recruitment for clinical trials across a range of therapeutic areas and development stages.
TriNetX connects healthcare organizations, biopharmaceutical companies, and contract research organizations to collaborate, enhance trial design, accelerate patient recruitment, conduct in-depth research, and help bring new therapies to market faster.
Through TriNetX's cloud-based platform, researchers are able to analyze patient populations and perform "what-if" analyses in real-time.
Users of the platform are presented with aggregate views, but each data point in the network can be traced to healthcare organizations who have the ability to identify patients, allowing clinical researchers to develop virtual patient cohorts for potential recruitment into a clinical trial.
The TriNetX network will help Pfizer to recruit hard-to-find patients with rare diseases and to identify sites with access to patients who meet inclusion and exclusion criteria.
Pfizer discovers, develops, manufactures, and sells healthcare products worldwide. Its global portfolio includes medicines and vaccines as well as consumer health care products. The company collaborates with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world.
Each member of the TriNetX community shares in the consolidated value of its global, federated health research network that connects clinical researchers in real-time to the patient populations which they are attempting to study.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study